Earnings call transcript: DiaMedica Q2 2026 loss matches forecast as trials advance
AI Summary
DiaMedica reported its Q2 2026 financial loss in line with forecasts as clinical trials for their treatments progress as expected.
Related Articles
FG initiative targets capital gap in Nigeria’s creative economy
Punch Nigeria —
Freeport-McMoRan: Growth On The Horizon, With A Positive Q2 As Significant Growth Operations Continue
Seeking Alpha —
Russian airlines carry nearly 50 mln passengers in H1 2026 — regulator
TASS —
Freeport-McMoRan: Robust Q2, Grasberg Ramp-Up, And Copper Near All-Time Highs
Seeking Alpha —
Yankees, Apollo Sports Capital agree to $2.6B financing deal
Yahoo Sports —
New York Yankees, Apollo Agree on $2.6B Capital Injection, Investment
Yahoo Sports —